$0.66
1.89%
Downside
Day's Volatility :8.16%
Upside
6.38%
22.73%
Downside
52 Weeks Volatility :73.71%
Upside
65.98%
Period | Sensei Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -33.46% | 6.5% | 0.0% |
6 Months | -15.16% | 7.1% | 0.0% |
1 Year | -46.98% | 9.8% | 0.0% |
3 Years | -91.08% | 14.2% | -20.2% |
Market Capitalization | 16.5M |
Book Value | $2.33 |
Earnings Per Share (EPS) | -1.21 |
Wall Street Target Price | 4.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.83% |
Return On Equity TTM | -41.63% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -33.4M |
Diluted Eps TTM | -1.21 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.12 |
EPS Estimate Next Year | -1.14 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | -0.24 |
What analysts predicted
Upside of 543.94%
Sell
Neutral
Buy
Sensei Biotherapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Sensei Biotherapeutics Inc | 1.47% | -15.16% | -46.98% | -91.08% | -96.41% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Sensei Biotherapeutics Inc | NA | NA | NA | -1.12 | -0.42 | -0.25 | NA | 2.33 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Sensei Biotherapeutics Inc | Buy | $16.5M | -96.41% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Sensei Biotherapeutics Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 108.6%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 277.6%
Newtyn Management LLC
Vanguard Group Inc
Renaissance Technologies Corp
Geode Capital Management, LLC
Bridgeway Capital Management, LLC
Bank of America Corp
sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit
Organization | Sensei Biotherapeutics Inc |
Employees | 27 |
CEO | Mr. John K. Celebi M.B.A. |
Industry | Services |
Iheartmedia
$0.66
-2.64%
Gigacloud Technology Inc
$0.66
-2.64%
Qurate Retail Inc
$0.66
-2.64%
Madison Square Garden Entertainment Corp
$0.66
-2.64%
Xpel Inc
$0.66
-2.64%
Telecom Argentina S.a.
$0.66
-2.64%
Barrett Business Services Inc
$0.66
-2.64%
Stitch Fix, Inc. (class A Shares)
$0.66
-2.64%
Jack In The Box Inc.
$0.66
-2.64%